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[Location]: current incorrect text printed in article Text should correctly read
[p. 551, Abstract]:
VI 25 mg significantly improved wm and trough FEV1 vs.
placebo (209 ml and 131 ml, respectively).
VI 25 mg significantly improved wm and trough FEV1 vs.
placebo (185 ml and 100 ml, respectively).
[p. 552, Safety evaluation]:
(n Z 406; UC population)
(n Z 407; UC population)
[p. 553, Figure 1]:
FF/VI 200/25 vs. FF 100
FF/VI 200/25 vs. FF 200
[p. 554, Table 1. SD value for age in FF/VI 200/25 group]:
[8.58]
[8.67]
[p. 555, Table 2. Footnote]:
CRQ-SAS dyspnoea domain is scaled from 0 to 7,
with 0 indicating no impairment
CRQ-SAS dyspnoea domain is scaled from 1 to 7, with
1 indicating no impairment
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